Healthcare PharmaceuticalsBlockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals. FDA approved in 2017. Over 1.4 million active patients worldwide. Global net sales of $17.8 billion in 2025.
immunologyatopic-dermatitisdupilumab